BACKGROUND: Aboriginals are over-represented in Canada's HIV epidemic and are commonly infected with HIV via injection drug use (IDU); however, little is known about the impact of Aboriginal ethnicity on mortality after starting highly active antiretroviral therapy (HAART). Therefore, we compared mortality rates between Aboriginal and non-Aboriginal HIV patients and between IDU and non-IDU HIV patients after they initiated HAART. METHODS: We conducted a retrospective cohort study of antiretroviral-naïve patients starting HAART January 1999-June 2005 (baseline), followed until December 2005. We constructed two Cox proportional hazards models, one to estimate all-cause and one to estimate HIV-related mortality hazard ratios (HRs), considering sex, and baseline age, CD4 cell count, HIV RNA level, calendar year, and HAART regimen as potential confounders. RESULTS: The 548 study patients were followed for 1,889.8 person-years; 194 (35%) were Aboriginal, 255 (46%) were IDUs. We observed 55 deaths; 47% were HIV-related. In multivariable models, Aboriginals experienced higher all-cause (HR = 1.85, 95% CI = 1.05-3.26, p = 0.034) and HIV-related (HR = 3.47, 95% CI = 1.36-8.83, p = 0.009) mortality rates compared to non-Aboriginals; and, compared to patients with other exposures, IDUs experienced higher all-cause (HR = 2.45, 95% CI = 1.31-4.57, p = 0.005) but similar HIV-related (p = 0.27) mortality rates. CONCLUSIONS: Compared to non-Aboriginals, Aboriginal HIV patients suffer higher all-cause and HIV-related mortality rates after starting HAART. The strongest and most significant predictor of higher all-cause mortality was IDU. Future research should examine reasons for the observed poorer survival of Aboriginal and IDU HIV patients after initiating HAART to develop interventions to improve the prognosis for these vulnerable populations.
BACKGROUND: Aboriginals are over-represented in Canada's HIV epidemic and are commonly infected with HIV via injection drug use (IDU); however, little is known about the impact of Aboriginal ethnicity on mortality after starting highly active antiretroviral therapy (HAART). Therefore, we compared mortality rates between Aboriginal and non-Aboriginal HIVpatients and between IDU and non-IDU HIVpatients after they initiated HAART. METHODS: We conducted a retrospective cohort study of antiretroviral-naïve patients starting HAART January 1999-June 2005 (baseline), followed until December 2005. We constructed two Cox proportional hazards models, one to estimate all-cause and one to estimate HIV-related mortality hazard ratios (HRs), considering sex, and baseline age, CD4 cell count, HIV RNA level, calendar year, and HAART regimen as potential confounders. RESULTS: The 548 study patients were followed for 1,889.8 person-years; 194 (35%) were Aboriginal, 255 (46%) were IDUs. We observed 55 deaths; 47% were HIV-related. In multivariable models, Aboriginals experienced higher all-cause (HR = 1.85, 95% CI = 1.05-3.26, p = 0.034) and HIV-related (HR = 3.47, 95% CI = 1.36-8.83, p = 0.009) mortality rates compared to non-Aboriginals; and, compared to patients with other exposures, IDUs experienced higher all-cause (HR = 2.45, 95% CI = 1.31-4.57, p = 0.005) but similar HIV-related (p = 0.27) mortality rates. CONCLUSIONS: Compared to non-Aboriginals, Aboriginal HIVpatients suffer higher all-cause and HIV-related mortality rates after starting HAART. The strongest and most significant predictor of higher all-cause mortality was IDU. Future research should examine reasons for the observed poorer survival of Aboriginal and IDU HIVpatients after initiating HAART to develop interventions to improve the prognosis for these vulnerable populations.
Authors: H Liu; C E Golin; L G Miller; R D Hays; C K Beck; S Sanandaji; J Christian; T Maldonado; D Duran; A H Kaplan; N S Wenger Journal: Ann Intern Med Date: 2001-05-15 Impact factor: 25.391
Authors: M Angeles Rodríguez-Arenas; Inmaculada Jarrín; Julia del Amo; José A Iribarren; Santiago Moreno; Pompeyo Viciana; Alejandro Peña; José L Gómez Sirvent; Francesc Vidal; José Lacruz; Félix Gutierrez; José A Oteo; Román Asencio; Jesús Castilla; Santiago Perez Hoyos Journal: AIDS Res Hum Retroviruses Date: 2006-08 Impact factor: 2.205
Authors: N Voirin; C Trépo; P Miailhes; J L Touraine; C Chidiac; D Peyramond; J M Livrozet; J Ritter; P Chevallier; J Fabry; R Allard; P Vanhems Journal: J Viral Hepat Date: 2004-11 Impact factor: 3.728
Authors: Robert S Hogg; Katherine Heath; David Bangsberg; Benita Yip; Natasha Press; Michael V O'Shaughnessy; Julio S G Montaner Journal: AIDS Date: 2002-05-03 Impact factor: 4.177
Authors: Manuel Alcoba; Maria J Cuevas; Maria-Rosario Perez-Simon; Jose-Luis Mostaza; Luis Ortega; Juan Ortiz de Urbina; Jose A Carro; Carmen Raya; Miriam Abad; Vicente Martin Journal: J Acquir Immune Defic Syndr Date: 2003-06-01 Impact factor: 3.731
Authors: C A Kleeberger; J P Phair; S A Strathdee; R Detels; L Kingsley; L P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2001-01-01 Impact factor: 3.731
Authors: Margaret May; Jonathan A C Sterne; Caroline Sabin; Dominique Costagliola; Amy C Justice; Rodolphe Thiébaut; John Gill; Andrew Phillips; Peter Reiss; Robert Hogg; Bruno Ledergerber; Antonella D'Arminio Monforte; Norbert Schmeisser; Shlomo Staszewski; Matthias Egger Journal: AIDS Date: 2007-05-31 Impact factor: 4.177
Authors: Brigg Reilley; Emily Bloss; Kathy K Byrd; Jonathan Iralu; Lisa Neel; James Cheek Journal: Am J Public Health Date: 2014-04-22 Impact factor: 9.308
Authors: Brittany Barker; Evan Adams; Evan Wood; Thomas Kerr; Kora DeBeck; Huiru Dong; Jean Shoveller; Julio Montaner; M-J Milloy Journal: AIDS Behav Date: 2019-05
Authors: Surita Parashar; Alexandra B Collins; Julio S G Montaner; Robert S Hogg; Michael-John Milloy Journal: Curr Opin HIV AIDS Date: 2016-09 Impact factor: 4.283
Authors: Sophie Patterson; Angela Cescon; Hasina Samji; Keith Chan; Wendy Zhang; Janet Raboud; Ann N Burchell; Curtis Cooper; Marina B Klein; Sean B Rourke; Mona R Loutfy; Nima Machouf; Julio S G Montaner; Chris Tsoukas; Robert S Hogg Journal: BMC Infect Dis Date: 2015-07-17 Impact factor: 3.090